University of Gothenburg research suggests blocking somatostatin may prevent hypoglycemia in type 1 diabetes patients.

Research from the University of Gothenburg, published in "Nature Metabolism," suggests that blocking the hormone somatostatin may prevent dangerous blood sugar drops in type 1 diabetes. In patients, excess somatostatin inhibits glucagon release, leading to hypoglycemia. Experiments with mice showed that inhibiting somatostatin restored glucagon release, highlighting a new potential treatment strategy that could reduce life-threatening low blood sugar risks.

September 30, 2024
8 Articles